Compare AbCellera Biologics Inc (ABCL) vs TeraWulf Inc (WULF) Price & Performance

AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.

The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.

WULF trades at $22.21, up 4.86% with strong analyst support despite bearish technical signals. The company recently secured a transformative $19 billion AI infrastructure deal with Anthropic, shifting focus from Bitcoin mining to long-term contracted revenue. However, fundamentals show significant challenges with negative profit margins (-611.46%) and high valuation ratios (P/S 53.86, P/B 84.25) amid consecutive earnings misses.

The outlook balances substantial AI opportunity against current financial weakness. The 20-year Anthropic contract provides revenue visibility, but execution risks and negative cash flow from operations (-$123M) require careful monitoring. With 100% analyst buy ratings and $32.40 consensus target offering 46% upside, the stock presents high-risk, high-reward potential for investors believing in the AI infrastructure pivot.